The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS).
 
Gregory Michael Cote
Consulting or Advisory Role - BioAtla; C4 Therapeutics; Daiichi Sankyo/UCB Japan; Eisai; Foghorn Therapeutics; Ikena Oncology
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); BioAtla (Inst); C4 Therapeutics (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); Repare Therapeutics (Inst); Servier (Inst); Springworks Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Candace L. Haddox
Research Funding - HiFiBiO Therapeutics (Inst); Roche/Genentech (Inst); Tango Therapeutics (Inst)
 
Edwin Choy
Consulting or Advisory Role - Adaptimmune; Bayer; Daiichi Sankyo; Epizyme
Research Funding - Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Exelixis (Inst); Immune Design (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Priscilla Merriam
Research Funding - Mereo BioPharma (Inst); SpringWorks Therapeutics (Inst)
 
Emanuele Mazzola
No Relationships to Disclose
 
Andrew J. Wagner
Consulting or Advisory Role - AADi; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; InhibRx; Lilly; Mundipharma; SERVIER
Research Funding - AADi (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst); Rain Therapeutics (Inst)
 
Brittany L. Siontis
No Relationships to Disclose
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BTG (Inst); C4 Therapeutics (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Incyte (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Monopar Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); Salarius Pharmaceuticals (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
 
Mahesh Seetharam
Stock and Other Ownership Interests - BioNTech; crispr therapeutics; Moderna Therapeutics
Honoraria - AADi; Daiichi Sankyo; Deciphera; Horizon CME
 
George D. Demetri
Leadership - Blueprint Medicines; Translate BIO
Stock and Other Ownership Interests - Acrivon Therapeutics; Bessor Pharma; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Champions Oncology; Erasca, Inc; G1 Therapeutics; IDRx; Ikena Oncology; Kojin Therapeutics; Relay Therapeutics; Translate BIO
Consulting or Advisory Role - AADi; Acrivon Therapeutics; Arsenal Capital; Bayer; Blueprint Medicines; C4 Therapeutics; Caprion/HistoGeneX; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Epizyme; G1 Therapeutics; GlaxoSmithKline; IDRx; Ikena Oncology; Janssen Oncology; Jazz Pharmaceuticals; Kojin Therapeutics; McCann Health; Medscape; Merck KGaA; Mirati Therapeutics; MJH Associates; Novartis; Pfizer; PharmaMar; Rain Therapeutics; Relay Therapeutics; Roche/Genentech; Synlogic; WIRB-Copernicus Group
Research Funding - Adaptimmune (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis
Travel, Accommodations, Expenses - Alexandria Real-Estate Summit
(OPTIONAL) Uncompensated Relationships - AACR; Alexandria Real-Estate Summit
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Honoraria - CStone Pharmaceuticals
Consulting or Advisory Role - Bayer; BioAtla; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - BioAtla; Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); IDRx (Inst); Merck (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG